Denise Yardley, MD | Authors

February 03, 2018

Denise Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, offers advice to community oncologists on managing patients.

December 16, 2017

Denise Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses the role of enzalutamide in hormone-receptor positive (HR+) advanced breast cancer.

December 07, 2017

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer.

June 06, 2017

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the APHINITY trial, which compared chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer.

May 10, 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the role of nab-paclitaxel (Abraxane) in the treatment of triple-negative breast cancer (TNBC).

January 13, 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the phase II tnAcity trial in triple-negative breast cancer.